{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:43:24Z","timestamp":1787726604412,"version":"build-2784847793"},"reference-count":323,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["TA200524"],"award-info":[{"award-number":["TA200524"]}],"id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["TA200322"],"award-info":[{"award-number":["TA200322"]}],"id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000382","name":"Society for Endocrinology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.beem.2024.101892","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T13:38:45Z","timestamp":1710337125000},"page":"101892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Genetic diagnosis in acromegaly and gigantism: From research to clinical practice"],"prefix":"10.1016","volume":"38","author":[{"given":"Claudia","family":"Ram\u00edrez-Renter\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Hern\u00e1ndez-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2024.101892_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-15-1064","article-title":"Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas","volume":"174","author":"Ronchi","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beem.2024.101892_bib3","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1210\/jc.2005-2671","article-title":"Clinical characterization of familial isolated pituitary adenomas","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib4","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1126\/science.1126100","article-title":"Pituitary adenoma predisposition caused by germline mutations in the AIP gene","volume":"312","author":"Vierimaa","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.beem.2024.101892_bib5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/ERC-15-0320","article-title":"Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients","volume":"22","author":"Rostomyan","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib6","article-title":"Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations","author":"Korbonits","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib7","series-title":"GeneReviews [Internet]","article-title":"Multiple endocrine neoplasia type 1","author":"Giusti","year":"2005"},{"key":"10.1016\/j.beem.2024.101892_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/endrev\/bnaa031","article-title":"Multiple endocrine neoplasia type 1: Latest insights","volume":"42","author":"Brandi","year":"2021","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2024.101892_bib9","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1029041","article-title":"Beyond the \"3 Ps\": a critical appraisal of the non-endocrine manifestations of multiple endocrine neoplasia type 1","volume":"13","author":"Waguespack","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.beem.2024.101892_bib11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/qjmed\/89.9.653","article-title":"Clinical studies of multiple endocrine neoplasia type 1 (MEN1)","volume":"89","author":"Trump","year":"1996","journal-title":"QJM"},{"key":"10.1016\/j.beem.2024.101892_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/humu.20605","article-title":"Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene","volume":"29","author":"Lemos","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.beem.2024.101892_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cancergen.2015.12.002","article-title":"Multiple endocrine neoplasia type 1 (MEN1): an update of 208 new germline variants reported in the last nine years","volume":"209","author":"Concolino","year":"2016","journal-title":"Cancer Genet"},{"key":"10.1016\/j.beem.2024.101892_bib14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.beem.2024.101892_bib15","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/6.7.1177","article-title":"Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1","volume":"6","author":"Lemmens","year":"1997","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.beem.2024.101892_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.40.5.e72","article-title":"Mutational and gross deletion study of the MEN1 gene and correlation with clinical features in Spanish patients","volume":"40","author":"Cebrian","year":"2003","journal-title":"J Med Genet"},{"key":"10.1016\/j.beem.2024.101892_bib17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12916-016-0708-1","article-title":"MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients","volume":"14","author":"de Laat","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.beem.2024.101892_bib18","doi-asserted-by":"crossref","first-page":"K15","DOI":"10.1530\/EJE-18-0778","article-title":"Germline and somatic mosaicism in a family with multiple endocrine neoplasia type 1 (MEN1) syndrome","volume":"180","author":"Beijers","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib19","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1530\/EJE-18-0852","article-title":"Diagnosis of mosaic mutations in the MEN1 gene by next generation sequencing","volume":"180","author":"Coppin","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1210\/jc.2018-01170","article-title":"UMD-MEN1 database: an overview of the 370 MEN1 variants present in 1676 patients from the French population","volume":"104","author":"Romanet","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1055\/s-2007-970160","article-title":"Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1","volume":"115","author":"Schaaf","year":"2007","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.beem.2024.101892_bib22","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1073\/pnas.95.4.1630","article-title":"Menin, the product of the MEN1 gene, is a nuclear protein","volume":"95","author":"Guru","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beem.2024.101892_bib23","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1038\/sj.onc.1209400","article-title":"Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression","volume":"25","author":"La","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.beem.2024.101892_bib24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tibs.2013.05.005","article-title":"Menin: a scaffold protein that controls gene expression and cell signaling","volume":"38","author":"Matkar","year":"2013","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.beem.2024.101892_bib25","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0002-9343(87)90008-8","article-title":"Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1","volume":"82","author":"Benson","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2024.101892_bib26","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1067\/msy.1998.93107","article-title":"The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1","volume":"124","author":"Carty","year":"1998","journal-title":"Surgery"},{"key":"10.1016\/j.beem.2024.101892_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","article-title":"Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study","volume":"87","author":"Verges","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2265.2007.02934.x","article-title":"Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers","volume":"67","author":"Machens","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib29","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1210\/JC.2015-2015","article-title":"Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 study group (DMSG)","volume":"100","author":"de Laat","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib30","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3171\/2020.1.JNS193538","article-title":"Pituitary adenomas in the setting of multiple endocrine neoplasia type 1: a single-institution experience","volume":"134","author":"Cohen-Cohen","year":"2020","journal-title":"J Neurosurg"},{"key":"10.1016\/j.beem.2024.101892_bib31","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/EJE-21-0630","article-title":"Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study","volume":"185","author":"Le Bras","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib32","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/PAS.0b013e31815ade45","article-title":"Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients","volume":"32","author":"Trouillas","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.beem.2024.101892_bib33","doi-asserted-by":"crossref","first-page":"E1905","DOI":"10.1210\/jc.2011-1127","article-title":"Unique gene expression profile associated with an early-onset multiple endocrine neoplasia (MEN1)-associated pituitary adenoma","volume":"96","author":"Farrell","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib34","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1210\/clinem\/dgaa800","article-title":"The management of neuroendocrine tumors of the lung in MEN1: results from the Dutch MEN1 study group","volume":"106","author":"van den Broek","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib35","first-page":"4776","article-title":"Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1","volume":"85","author":"Stratakis","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib36","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1210\/jc.2014-3659","article-title":"MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d\u2019Etude des Tumeurs Endocrines","volume":"100","author":"Goudet","year":"2015","journal-title":"J Clin Endocr Metab"},{"key":"10.1016\/j.beem.2024.101892_bib37","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12020-017-1322-5","article-title":"MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors","volume":"59","author":"Vannucci","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101892_bib38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/cen.14067","article-title":"Paediatric and young adult manifestations and outcomes of multiple endocrine neoplasia type 1","volume":"91","author":"Herath","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.surg.2021.04.041","article-title":"Multiple endocrine neoplasia type 1 in children and adolescents: Clinical features and treatment outcomes","volume":"171","author":"Shariq","year":"2022","journal-title":"Surgery"},{"key":"10.1016\/j.beem.2024.101892_bib40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-12-0763","article-title":"Genetic analysis in young patients with sporadic pituitary macroadenomas: Beside AIP don't forget MEN1 genetic analysis","volume":"168","author":"Cuny","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/EJE-21-0075","article-title":"Clinical and genetic characteristics in patients under 30 years with sporadic pituitary adenomas","volume":"185","author":"Martinez de LaPiscina","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib42","doi-asserted-by":"crossref","first-page":"e2271","DOI":"10.1210\/clinem\/dgaa142","article-title":"Clinical MEN-1 among a large cohort of patients with acromegaly","volume":"105","author":"Nachtigall","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib43","first-page":"743","article-title":"Osteitis fibrosa cystica: the case of a nine year old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism","volume":"52","author":"McCune","year":"1936","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.beem.2024.101892_bib44","series-title":"McCune-Albright syndrome","article-title":"Fibrous dysplasia","author":"Boyce","year":"2019"},{"key":"10.1016\/j.beem.2024.101892_bib45","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad744","article-title":"Incidence and prevalence of fibrous dysplasia\/McCune-Albright syndrome - a nationwide registry-based study in Denmark","author":"Meier","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib46","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","article-title":"Activating mutations of the stimulatory G protein in the McCune-Albright syndrome","volume":"325","author":"Weinstein","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101892_bib47","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1210\/jc.2003-031225","article-title":"Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study","volume":"89","author":"Lumbroso","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib48","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2559.2007.02676.x","article-title":"A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone","volume":"50","author":"Idowu","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.beem.2024.101892_bib49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1210\/endrev\/bnz011","article-title":"Fibrous dysplasia\/McCune-Albright syndrome: a rare, mosaic disease of Galpha s activation","volume":"41","author":"Boyce","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2024.101892_bib50","doi-asserted-by":"crossref","first-page":"15475","DOI":"10.1073\/pnas.95.26.15475","article-title":"Bidirectional imprinting of a single gene: GNAS1 encodes maternally, paternally, and biallelically derived proteins","volume":"95","author":"Hayward","year":"1998","journal-title":"Proc Natl Acad Sci Usa"},{"key":"10.1016\/j.beem.2024.101892_bib51","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/hmg\/9.5.835","article-title":"An imprinted antisense transcript at the human GNAS1 locus","volume":"9","author":"Hayward","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.beem.2024.101892_bib52","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1210\/jc.2002-020183","article-title":"The gsalpha gene: predominant maternal origin of transcription in human thyroid gland and gonads","volume":"87","author":"Mantovani","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000504802","article-title":"The clinical spectrum of McCune-Albright syndrome and its management","volume":"92","author":"Spencer","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.beem.2024.101892_bib54","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/340692a0","article-title":"GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours","volume":"340","author":"Landis","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.beem.2024.101892_bib55","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1006\/frne.1993.1007","article-title":"G-proteins and hormonal signalling in human pituitary tumors: genetic mutations and functional alterations","volume":"14","author":"Spada","year":"1993","journal-title":"Front Neuroendocr"},{"key":"10.1016\/j.beem.2024.101892_bib56","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/369621a0","article-title":"Structural determinants for activation of the alpha-subunit of a heterotrimeric G protein","volume":"369","author":"Lambright","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.beem.2024.101892_bib57","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrm908","article-title":"Seven-transmembrane receptors","volume":"3","author":"Pierce","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.beem.2024.101892_bib58","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/JME-13-0172","article-title":"cAMP in the pituitary: an old messenger for multiple signals","volume":"52","author":"Peverelli","year":"2014","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib59","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1210\/jc.2013-3826","article-title":"Acromegaly and McCune-Albright syndrome","volume":"99","author":"Salenave","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib60","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1210\/jc.2001-012022","article-title":"Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome","volume":"87","author":"Akintoye","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF00689340","article-title":"Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis","volume":"403","author":"Kovacs","year":"1984","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"10.1016\/j.beem.2024.101892_bib62","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1210\/jc.2012-1274","article-title":"Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome","volume":"97","author":"Vortmeyer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib63","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00005792-198507000-00007","article-title":"The complex of myxomas, spotty pigmentation, and endocrine overactivity","volume":"64","author":"Carney","year":"1985","journal-title":"Med (Baltim)"},{"key":"10.1016\/j.beem.2024.101892_bib64","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1210\/jcem.86.9.7903","article-title":"Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation","volume":"86","author":"Stratakis","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib65","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1210\/jc.2008-2333","article-title":"Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes","volume":"94","author":"Bertherat","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib66","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1172\/JCI10841","article-title":"Mutations in the protein kinase A R1alpha regulatory subunit cause familial cardiac myxomas and Carney complex","volume":"106","author":"Casey","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beem.2024.101892_bib67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/79238","article-title":"Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex","volume":"26","author":"Kirschner","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2024.101892_bib68","first-page":"D678","article-title":"Specificity in the cAMP\/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA","volume":"5","author":"Skalhegg","year":"2000","journal-title":"Front Biosci"},{"key":"10.1016\/j.beem.2024.101892_bib69","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1021\/cr000236l","article-title":"Physiological substrates of cAMP-dependent protein kinase","volume":"101","author":"Shabb","year":"2001","journal-title":"Chem Rev"},{"key":"10.1016\/j.beem.2024.101892_bib70","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1749-6632.2002.tb04328.x","article-title":"The essential role of RI alpha in the maintenance of regulated PKA activity","volume":"968","author":"Amieux","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.beem.2024.101892_bib71","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.mce.2010.11.018","article-title":"How does cAMP\/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?","volume":"336","author":"Almeida","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib72","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMc1309730","article-title":"PRKACB and Carney complex","volume":"370","author":"Forlino","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101892_bib73","doi-asserted-by":"crossref","first-page":"E183","DOI":"10.1210\/jc.2013-3159","article-title":"Deletions of the PRKAR1A locus at 17q24.2-q24.3 in Carney complex: genotype-phenotype correlations and implications for genetic testing","volume":"99","author":"Salpea","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib74","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1172\/JCI118467","article-title":"Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2","volume":"97","author":"Stratakis","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beem.2024.101892_bib75","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1093\/hmg\/9.20.3037","article-title":"Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex","volume":"9","author":"Kirschner","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.beem.2024.101892_bib76","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000345669","article-title":"Carney complex","volume":"41","author":"Espiard","year":"2013","journal-title":"Front Horm Res"},{"key":"10.1016\/j.beem.2024.101892_bib77","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mce.2010.04.027","article-title":"PRKAR1A and the evolution of pituitary tumors","volume":"326","author":"Kirschner","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib78","doi-asserted-by":"crossref","first-page":"E496","DOI":"10.1210\/jc.2011-2220","article-title":"In vitro studies of novel PRKAR1A mutants that extend the predicted RIalpha protein sequence into the 3'-untranslated open reading frame: proteasomal degradation leads to RIalpha haploinsufficiency and Carney complex","volume":"97","author":"Patronas","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib79","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mce.2017.08.006","article-title":"Cyclic 3',5'-adenosine monophosphate (cAMP) signaling in the anterior pituitary gland in health and disease","volume":"463","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib80","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa002","article-title":"Frequency and incidence of Carney complex manifestations: A prospective multicenter study with a three-year follow-up","volume":"105","author":"Espiard","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib81","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1515\/JPEM.2000.13.4.374","article-title":"Prolactin secretion abnormalities in patients with the \"syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas\" (Carney complex)","volume":"13","author":"Raff","year":"2000","journal-title":"J Pediatr Endocrinol Metab: JPEM"},{"key":"10.1016\/j.beem.2024.101892_bib82","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3171\/jns.2000.92.3.0413","article-title":"Neurosurgical implications of Carney complex","volume":"92","author":"Watson","year":"2000","journal-title":"J Neurosurg"},{"key":"10.1016\/j.beem.2024.101892_bib83","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1046\/j.1365-2133.1997.d01-1239.x","article-title":"Carney complex: report of a kindred with predominantly cutaneous manifestations","volume":"136","author":"Armstrong","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.beem.2024.101892_bib84","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJMcpc010057","article-title":"Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 11-2002. A 27-year-old woman with two intracardiac masses and a history of endocrinopathy","volume":"346","author":"Basson","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101892_bib85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11102-005-5348-y","article-title":"Pituitary pathology in Carney complex patients","volume":"7","author":"Stergiopoulos","year":"2004","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101892_bib86","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1210\/js.2017-00231","article-title":"Corticotropinoma as a component of Carney complex","volume":"1","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2017","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2024.101892_bib87","doi-asserted-by":"crossref","first-page":"K7","DOI":"10.1530\/EJE-17-0227","article-title":"PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex","volume":"177","author":"Kiefer","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib88","first-page":"3860","article-title":"Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the \"complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas\" (Carney complex)","volume":"85","author":"Pack","year":"2000","journal-title":"J Clin Endocr Metab"},{"key":"10.1016\/j.beem.2024.101892_bib89","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1227\/NEU.0000000000001384","article-title":"Surgical management of Carney complex-associated pituitary pathology","volume":"80","author":"Lonser","year":"2017","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2024.101892_bib90","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2265.2002.01643.x","article-title":"Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours","volume":"57","author":"Kaltsas","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.39.12.e78","article-title":"PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex","volume":"39","author":"Sandrini","year":"2002","journal-title":"J Med Genet"},{"key":"10.1016\/j.beem.2024.101892_bib92","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2265.2003.01740.x","article-title":"GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23-24","volume":"58","author":"Yamasaki","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib93","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1399-0004.2010.01406.x","article-title":"The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes","volume":"78","author":"Stratakis","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.beem.2024.101892_bib94","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s11102-019-00974-8","article-title":"Acromegaly in Carney complex","volume":"22","author":"Cuny","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101892_bib95","doi-asserted-by":"crossref","first-page":"15558","DOI":"10.1073\/pnas.0603877103","article-title":"Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans","volume":"103","author":"Pellegata","year":"2006","journal-title":"Proc Natl Acad Sci Usa"},{"key":"10.1016\/j.beem.2024.101892_bib96","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1210\/jc.2006-2843","article-title":"Germline CDKN1B\/p27Kip1 mutation in multiple endocrine neoplasia","volume":"92","author":"Georgitsi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib97","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1210\/jc.2008-2083","article-title":"Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states","volume":"94","author":"Agarwal","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib98","doi-asserted-by":"crossref","first-page":"E1825","DOI":"10.1002\/humu.21354","article-title":"A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization","volume":"31","author":"Molatore","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.beem.2024.101892_bib99","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2265.2011.04269.x","article-title":"Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain","volume":"76","author":"Belar","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib100","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1530\/EJE-11-0929","article-title":"Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia (MEN)-like phenotype","volume":"166","author":"Malanga","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003350","article-title":"A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype","volume":"9","author":"Occhi","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.beem.2024.101892_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EC-14-0116","article-title":"Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4 (MEN4)","volume":"4","author":"Pardi","year":"2015","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2024.101892_bib103","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12020-015-0540-y","article-title":"Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region","volume":"49","author":"Sambugaro","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101892_bib104","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1210\/jc.2019-00082","article-title":"Clinical features of multiple endocrine neoplasia type 4: Novel pathogenic variant and review of published cases","volume":"104","author":"Frederiksen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1530\/ERC-11-0362","article-title":"Cyclin dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenomas (FIPA) kindreds","volume":"19","author":"Tichomirowa","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib106","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s12020-016-0941-6","article-title":"Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas","volume":"55","author":"Borsari","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101892_bib107","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa160","article-title":"Germline CDKN1B loss-of-function variants cause pediatric Cushing's disease with or without an MEN4 phenotype","volume":"105","author":"Chasseloup","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib108","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0411","article-title":"Multiple endocrine neoplasia type 4: a new member of the MEN family","volume":"12","author":"Singeisen","year":"2023","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2024.101892_bib109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1101\/gad.8.1.9","article-title":"p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest","volume":"8","author":"Polyak","year":"1994","journal-title":"Genes Dev"},{"key":"10.1016\/j.beem.2024.101892_bib110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc2347","article-title":"The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy","volume":"8","author":"Chu","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib111","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.onc.1201516","article-title":"Mutation and expression analysis of the p27\/kip1 gene in corticotrophin-secreting tumours","volume":"16","author":"Dahia","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.beem.2024.101892_bib112","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1210\/jcem.84.10.6066","article-title":"Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors","volume":"84","author":"Lidhar","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib113","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/jcem.87.6.8517","article-title":"Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors","volume":"87","author":"Korbonits","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib114","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1530\/EJE-10-0327","article-title":"Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia","volume":"163","author":"Occhi","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib115","doi-asserted-by":"crossref","first-page":"E531","DOI":"10.1210\/jc.2014-3399","article-title":"Heterogeneous genetic background of the association of pheochromocytoma\/paraganglioma and pituitary adenoma: results from a large patient cohort","volume":"100","author":"Denes","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib116","doi-asserted-by":"crossref","first-page":"E710","DOI":"10.1210\/jc.2014-4297","article-title":"Pituitary adenoma with paraganglioma\/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice","volume":"100","author":"Xekouki","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib117","doi-asserted-by":"crossref","first-page":"T105","DOI":"10.1530\/ERC-15-0241","article-title":"15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas","volume":"22","author":"O'Toole","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib118","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cancergen.2021.03.008","article-title":"Invasive ACTH-producing pituitary gland neoplasm secondary to MSH2 mutation","volume":"256-257","author":"Loughrey","year":"2021","journal-title":"Cancer Genet"},{"key":"10.1016\/j.beem.2024.101892_bib119","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib120","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMc071191","article-title":"Familial gastrointestinal stromal tumors and germ-line mutations","volume":"357","author":"McWhinney","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101892_bib121","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.ejhg.5201904","article-title":"Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD","volume":"16","author":"Pasini","year":"2008","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.beem.2024.101892_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-13-0623","article-title":"Non-pheochromocytoma (PCC)\/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis","volume":"170","author":"Papathomas","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib123","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-17-0523","article-title":"DIAGNOSIS of ENDOCRINE DISEASE: SDHx mutations: beyond pheochromocytomas and paragangliomas","volume":"178","author":"Mannelli","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib124","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12020-018-1726-x","article-title":"Malignant paraganglioma and somatotropinoma in a patient with germline SDHB mutation-genetic and clinical features","volume":"63","author":"Saavedra","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101892_bib125","doi-asserted-by":"crossref","first-page":"E357","DOI":"10.1210\/jc.2011-1179","article-title":"Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH","volume":"97","author":"Xekouki","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib126","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1530\/ERC-22-0157","article-title":"Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours","volume":"29","author":"Loughrey","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib127","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.tibs.2017.01.003","article-title":"Mitochondrial complex II: at the crossroads","volume":"42","author":"Bezawork-Geleta","year":"2017","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.beem.2024.101892_bib128","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1371\/journal.pgen.0010008","article-title":"A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas","volume":"1","author":"Dahia","year":"2005","journal-title":"PLoS Genet"},{"key":"10.1016\/j.beem.2024.101892_bib129","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/MCB.01338-07","article-title":"Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis","volume":"28","author":"Guzy","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.beem.2024.101892_bib130","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1210\/me.2010-0256","article-title":"Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas","volume":"24","author":"Lopez-Jimenez","year":"2010","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib131","doi-asserted-by":"crossref","DOI":"10.1007\/s12022-017-9474-7","article-title":"Pituitary carcinoma in a patient with an SDHB mutation","author":"Tufton","year":"2017","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.beem.2024.101892_bib132","doi-asserted-by":"crossref","first-page":"24128","DOI":"10.1074\/jbc.M802996200","article-title":"Mitochondrial extrusion through the cytoplasmic vacuoles during cell death","volume":"283","author":"Nakajima","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beem.2024.101892_bib133","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2024.101892_bib134","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Comino-Mendez","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2024.101892_bib135","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beem.2024.101892_bib136","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/2159-8290.CD-13-0799","article-title":"MAX inactivation in small cell lung cancer disrupts MYC-SWI\/SNF programs and is synthetic lethal with BRG1","volume":"4","author":"Romero","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.beem.2024.101892_bib137","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1210\/jc.2015-2592","article-title":"Complex MAX rearrangement in a family with malignant pheochromocytoma, renal oncocytoma, and erythrocytosis","volume":"101","author":"Korpershoek","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib138","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/jnci\/djx238","article-title":"MAX mutations in endometrial cancer: clinicopathologic associations and recurrent MAX p.His28Arg functional characterization","volume":"110","author":"Walker","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beem.2024.101892_bib139","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3389\/fendo.2020.00558","article-title":"A novel phenotype of germline pathogenic variants in MAX: concurrence of pheochromocytoma and ganglioneuroma in a Chinese family and literature review","volume":"11","author":"Chang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.beem.2024.101892_bib140","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1210\/clinem\/dgaa957","article-title":"Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5?","volume":"106","author":"Seabrook","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib141","article-title":"A novel role for the extended MYC network in cancer cell survival","volume":"3","author":"Carroll","year":"2016","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.beem.2024.101892_bib142","doi-asserted-by":"crossref","first-page":"L37","DOI":"10.1530\/ERC-18-0065","article-title":"Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions","volume":"25","author":"Daly","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib143","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MAJ.0b013e3181e73fba","article-title":"Coincidence of multiple endocrine neoplasia type 2A with acromegaly","volume":"340","author":"Saito","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.beem.2024.101892_bib144","doi-asserted-by":"crossref","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.beem.2024.101892_bib145","series-title":"GeneReviews [Internet]","article-title":"Neurofibromatosis 1","author":"Friedman","year":"1998"},{"key":"10.1016\/j.beem.2024.101892_bib146","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.mcna.2019.07.004","article-title":"The diagnosis and management of neurofibromatosis type 1","volume":"103","author":"Ly","year":"2019","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.beem.2024.101892_bib147","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/0008-5472.CAN-04-4058","article-title":"Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors","volume":"65","author":"Dasgupta","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.beem.2024.101892_bib148","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR","volume":"102","author":"Johannessen","year":"2005","journal-title":"Proc Natl Acad Sci Usa"},{"key":"10.1016\/j.beem.2024.101892_bib149","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cen.13163","article-title":"Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1","volume":"86","author":"Gruber","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib150","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/hmg\/dds374","article-title":"Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma","volume":"21","author":"Burnichon","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.beem.2024.101892_bib151","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000369802","article-title":"Endocrine implications of neurofibromatosis 1 in childhood","volume":"83","author":"Bizzarri","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.beem.2024.101892_bib152","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/ajmg.a.38308","article-title":"Growth hormone excess in children with neurofibromatosis type-1 and optic glioma","volume":"173","author":"Cambiaso","year":"2017","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.beem.2024.101892_bib153","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000458525","article-title":"Endocrine long-term follow-up of children with neurofibromatosis type 1 and optic pathway glioma","volume":"87","author":"Sani","year":"2017","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.beem.2024.101892_bib154","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11082168","article-title":"Neurofibromatosis type 1 has a wide spectrum of growth hormone excess","volume":"11","author":"Hannah-Shmouni","year":"2022","journal-title":"J Clin Med"},{"issue":"78","key":"10.1016\/j.beem.2024.101892_bib155","first-page":"1427","article-title":"[Multiple tumours of the nervous system in Recklinghausen's disease. An anatomo-clinical case with chromophobe adenoma of the pituitary gland]","volume":"1970","author":"Boudin","year":"1893","journal-title":"Presse Med"},{"key":"10.1016\/j.beem.2024.101892_bib156","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinte.1980.00330150111026","article-title":"Prolactin-secreting pituitary tumor associated with von Recklinghausen's disease","volume":"140","author":"Pinnamaneni","year":"1980","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2024.101892_bib157","first-page":"278","article-title":"[Pituitary adenoma associated with neurofibromatosis: case report]","volume":"59","author":"Nakajima","year":"1990","journal-title":"Nihon Geka Hokan"},{"key":"10.1016\/j.beem.2024.101892_bib158","first-page":"741","article-title":"[Pituitary adenoma associated with neurofibromatosis type 1: case report]","volume":"30","author":"Kurozumi","year":"2002","journal-title":"No Shinkei Geka"},{"key":"10.1016\/j.beem.2024.101892_bib159","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.endonu.2012.01.020","article-title":"Acromegaly and type 1 neurofibromatosis. Is association of both conditions due to chance?","volume":"60","author":"Checa Garrido","year":"2013","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.beem.2024.101892_bib160","doi-asserted-by":"crossref","first-page":"E220","DOI":"10.1111\/ans.13108","article-title":"Non-functioning pituitary macroadenoma in a child with neurofibromatosis type 1","volume":"87","author":"Smith","year":"2017","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.beem.2024.101892_bib161","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1507\/endocrj.EJ19-0035","article-title":"Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1","volume":"66","author":"Hozumi","year":"2019","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2024.101892_bib162","doi-asserted-by":"crossref","first-page":"244","DOI":"10.32677\/IJCR.2021.v07.i06.008","article-title":"Incidentally detected pituitary macroadenoma in a case of neurofibromatosis type 1: A case report and review of literature","volume":"7","author":"Mishra","year":"2021","journal-title":"Indian J Case Rep"},{"key":"10.1016\/j.beem.2024.101892_bib163","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2169\/internalmedicine.4981-20","article-title":"Neurofibromatosis type 1 with concurrent multiple endocrine disorders: adenomatous goiter, primary hyperparathyroidism, and acromegaly","volume":"60","author":"Yasuda","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2024.101892_bib164","doi-asserted-by":"crossref","first-page":"SAT613","DOI":"10.1210\/jendso\/bvad114.1346","article-title":"A novel NF1 mutation as the underlying cause of dysmorphic features and acromegaly in an atypical case of neurofibromatosis type 1","volume":"7","author":"Alsagheir","year":"2023","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2024.101892_bib165","doi-asserted-by":"crossref","first-page":"SAT603","DOI":"10.1210\/jendso\/bvad114.1336","article-title":"A heterogeneous genetic background underlies familial and young-onset pituitary tumors","volume":"7","author":"Zuarth-Vazquez","year":"2023","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2024.101892_bib166","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cancergen.2021.03.004","article-title":"Somatic NF1 mutations in pituitary adenomas: Report of two cases","volume":"256-257","author":"Hong","year":"2021","journal-title":"Cancer Genet"},{"key":"10.1016\/j.beem.2024.101892_bib167","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12020-021-02954-0","article-title":"ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and review of the literature","volume":"76","author":"Sumislawski","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101892_bib168","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2024.101892_bib169","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","article-title":"Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations","volume":"123","author":"Northrup","year":"2021","journal-title":"Pedia Neurol"},{"key":"10.1016\/j.beem.2024.101892_bib170","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","volume":"75","author":"The European Chromosome 16 Tuberous Sclerosis Consortium","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.beem.2024.101892_bib171","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","article-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34","volume":"277","author":"van Slegtenhorst","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.beem.2024.101892_bib172","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1086\/302412","article-title":"High rate of mosaicism in tuberous sclerosis complex","volume":"64","author":"Verhoef","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2024.101892_bib173","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00439-010-0801-z","article-title":"Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex","volume":"127","author":"Qin","year":"2010","journal-title":"Hum Genet"},{"key":"10.1016\/j.beem.2024.101892_bib174","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00401-013-1085-x","article-title":"Evolving neurobiology of tuberous sclerosis complex","volume":"125","author":"Crino","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.beem.2024.101892_bib175","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.beem.2024.101892_bib176","doi-asserted-by":"crossref","first-page":"32493","DOI":"10.1074\/jbc.C300226200","article-title":"Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner","volume":"278","author":"Castro","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beem.2024.101892_bib177","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr Biol"},{"key":"10.1016\/j.beem.2024.101892_bib178","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","article-title":"TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1","volume":"47","author":"Dibble","year":"2012","journal-title":"Mol Cell"},{"key":"10.1016\/j.beem.2024.101892_bib179","first-page":"253","article-title":"[A case of tuberous sclerosis with acromegaly]","volume":"23","author":"Galaction-Nitelea","year":"1978","journal-title":"Rev Med Interna Neurol Psihiatr Neurochir Derm Neurol Psihiatr Neurochir"},{"key":"10.1016\/j.beem.2024.101892_bib180","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0022-3476(78)81170-6","article-title":"Acromegalic gigantism and tuberous sclerosis","volume":"93","author":"Hoffman","year":"1978","journal-title":"J Pediatr"},{"key":"10.1016\/j.beem.2024.101892_bib181","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archinte.1981.00340120121024","article-title":"Autonomous hyperprolactinemia in tuberous sclerosis","volume":"141","author":"Bloomgarden","year":"1981","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2024.101892_bib182","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1365-2265.2005.02374.x","article-title":"Simultaneous Cushing's disease and tuberous sclerosis; a potential role for TSC in pituitary ontogeny","volume":"63","author":"Tigas","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib183","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2265.2007.02941.x","article-title":"Cushing's syndrome due to a pituitary corticotropinoma in a child with tuberous sclerosis: an association or a coincidence","volume":"67","author":"Nandagopal","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib184","first-page":"2018","article-title":"Silent gonadotroph pituitary neuroendocrine tumor in a patient with tuberous sclerosis complex: evaluation of a possible molecular link","author":"Regazzo","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.beem.2024.101892_bib185","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1016\/j.gim.2022.08.021","article-title":"Genetic drivers of Cushing's disease: Frequency and associated phenotypes","volume":"24","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.beem.2024.101892_bib186","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1346-8138.1992.tb03741.x","article-title":"A rare association of localized gigantism with tuberous sclerosis","volume":"19","author":"Reddy","year":"1992","journal-title":"J Dermatol"},{"key":"10.1016\/j.beem.2024.101892_bib187","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1210\/jc.2013-1204","article-title":"Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update","volume":"98","author":"Wells","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib188","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.beem.2024.101892_bib189","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.beem.2024.101892_bib190","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/367375a0","article-title":"A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma","volume":"367","author":"Hofstra","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.beem.2024.101892_bib191","series-title":"GeneReviews [Internet].","article-title":"Multiple endocrine neoplasia type 2","author":"Eng","year":"1999"},{"key":"10.1016\/j.beem.2024.101892_bib192","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.bbapap.2012.10.008","article-title":"Structural studies of GDNF family ligands with their receptors-Insights into ligand recognition and activation of receptor tyrosine kinase RET","volume":"1834","author":"Wang","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.beem.2024.101892_bib193","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib194","doi-asserted-by":"crossref","first-page":"39159","DOI":"10.1074\/jbc.M006908200","article-title":"Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase","volume":"275","author":"Besset","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beem.2024.101892_bib195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.mce.2005.10.028","article-title":"Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside","volume":"247","author":"Machens","year":"2006","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib196","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","article-title":"The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis","volume":"276","author":"Eng","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2024.101892_bib197","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2265.1996.681503.x","article-title":"Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma","volume":"44","author":"Marsh","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib198","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/105072502320288393","article-title":"Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation","volume":"12","author":"Brauckhoff","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2024.101892_bib199","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1210\/me.2003-0173","article-title":"Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease","volume":"18","author":"Arighi","year":"2004","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib200","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2024.101892_bib201","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-8587(18)30336-X","article-title":"Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study","volume":"7","author":"Castinetti","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib202","article-title":"Multiple endocrine neoplasia 2a presenting with pheochromocytoma and pituitary macroadenoma","volume":"2011","author":"Heinlen","year":"2011","journal-title":"ISRN Oncol"},{"key":"10.1016\/j.beem.2024.101892_bib203","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/cen.12072","article-title":"Confusing genes: a patient with MEN2A and Cushing's disease","volume":"78","author":"Naziat","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib204","first-page":"1","article-title":"Cushing disease in a patient with multiple endocrine neoplasia type 2B","volume":"4","author":"Kasturi","year":"2017","journal-title":"J Clin Transl Endocrinol Case Rep"},{"key":"10.1016\/j.beem.2024.101892_bib205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031895","article-title":"The pathogenic RET Val804Met variant in acromegaly: a new clinical phenotype?","volume":"25","author":"Chiloiro","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beem.2024.101892_bib206","article-title":"Familial isolated pituitary adenomas unrelated to MEN1 mutations: A follow-up of 27 patients","author":"Valdes-Socin","year":"2000","journal-title":"10th Meet Belg Endocr Soc"},{"key":"10.1016\/j.beem.2024.101892_bib207","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-017-0725-8","article-title":"Frequency of familial pituitary adenoma syndromes among patients with functioning pituitary adenomas in a reference outpatient clinic","author":"Marques","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2024.101892_bib208","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib209","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib210","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/humu.21292","article-title":"Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families","volume":"31","author":"Igreja","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.beem.2024.101892_bib211","doi-asserted-by":"crossref","first-page":"E1242","DOI":"10.1210\/jc.2015-1869","article-title":"Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers","volume":"100","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib212","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1210\/jc.2006-2513","article-title":"Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families","volume":"92","author":"Daly","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib213","doi-asserted-by":"crossref","first-page":"E663","DOI":"10.1210\/jc.2011-2291","article-title":"Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients","volume":"97","author":"Cazabat","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib214","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17446651.2017.1306439","article-title":"Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening","volume":"12","author":"Iacovazzo","year":"2017","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib215","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/JOE-11-0054","article-title":"AIP and its interacting partners","volume":"210","author":"Trivellin","year":"2011","journal-title":"J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib216","doi-asserted-by":"crossref","first-page":"E1411","DOI":"10.1210\/jc.2012-1111","article-title":"Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway","volume":"97","author":"Chahal","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib217","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/onc.2014.50","article-title":"AIP inactivation leads to pituitary tumorigenesis through defective Galpha-cAMP signaling","volume":"34","author":"Tuominen","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.beem.2024.101892_bib218","doi-asserted-by":"crossref","first-page":"9177","DOI":"10.18632\/oncotarget.24183","article-title":"Multi-chaperone function modulation and association with cytoskeletal proteins are key features of the function of AIP in the pituitary gland","volume":"9","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.beem.2024.101892_bib219","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1038\/s41388-021-02009-8","article-title":"RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas","volume":"40","author":"Garcia-Rendueles","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.beem.2024.101892_bib220","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.celrep.2019.04.014","article-title":"Aryl hydrocarbon receptor interacting protein maintains germinal venter B cells through suppression of BCL6 degradation","volume":"27","author":"Sun","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.beem.2024.101892_bib221","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41416-022-01762-1","article-title":"Aryl-hydrocarbon receptor-interacting protein regulates tumorigenic and metastatic properties of colorectal cancer cells driving liver metastasis","volume":"126","author":"Solis-Fernandez","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib222","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1038\/s41388-019-0779-5","article-title":"Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors","volume":"38","author":"Barry","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.beem.2024.101892_bib223","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa040","article-title":"Significant benefits of AIP testing and clinical screening in familial isolated and young-onset pituitary tumors","volume":"105","author":"Marques","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib224","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1530\/ERC-11-0059","article-title":"Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation","volume":"18","author":"Villa","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000322787","article-title":"Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53","volume":"94","author":"Kasuki Jomori de Pinho","year":"2011","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2024.101892_bib226","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib227","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1210\/jc.2007-2611","article-title":"The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas","volume":"93","author":"Leontiou","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib228","doi-asserted-by":"crossref","first-page":"L11","DOI":"10.1530\/ERC-13-0218","article-title":"Familial pituitary apoplexy as the only presentation of a novel AIP mutation","volume":"20","author":"Xekouki","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib229","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa1408028","article-title":"Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation","volume":"371","author":"Trivellin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101892_bib230","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.beem.2018.02.004","article-title":"An orphan G-protein-coupled receptor causes human gigantism and\/or acromegaly: Molecular biology and clinical correlations","volume":"32","author":"Trivellin","year":"2018","journal-title":"Best Pr Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib231","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ajhg.2017.03.011","article-title":"Germline mutations in CDH23, encoding cadherin-related 23, are associated with both familial and sporadic pituitary adenomas","volume":"100","author":"Zhang","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2024.101892_bib232","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1166076","article-title":"Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion","volume":"14","author":"Trivellin","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.beem.2024.101892_bib233","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1111\/febs.16049","article-title":"PAM: diverse roles in neuroendocrine cells, cardiomyocytes, and green algae","volume":"289","author":"Back","year":"2022","journal-title":"FEBS J"},{"key":"10.1016\/j.beem.2024.101892_bib234","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/ERC-15-0038","article-title":"X-linked acrogigantism syndrome: clinical profile and therapeutic responses","volume":"22","author":"Beckers","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib235","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11102-016-0743-0","article-title":"Childhood acromegaly due to X-linked acrogigantism: long term follow-up","volume":"19","author":"Gordon","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101892_bib236","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1210\/jc.2019-00817","article-title":"Familial X-linked acrogigantism: postnatal outcomes and tumor pathology in a prenatally diagnosed infant and his mother","volume":"104","author":"Wise-Oringer","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib237","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11102-020-01105-4","article-title":"Genetics, clinical features and outcomes of non-syndromic pituitary gigantism: experience of a single center from Sao Paulo, Brazil","volume":"24","author":"Trarbach","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101892_bib238","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1159\/000512240","article-title":"A Chinese case of X-linked acrogigantism and systematic review","volume":"111","author":"Liang","year":"2021","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2024.101892_bib239","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40478-016-0328-1","article-title":"Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study","volume":"4","author":"Iacovazzo","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.beem.2024.101892_bib240","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1530\/ERC-16-0082","article-title":"Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects","volume":"23","author":"Daly","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib241","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ajhg.2022.02.002","article-title":"Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism","volume":"109","author":"Franke","year":"2022","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2024.101892_bib242","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1038\/s41467-020-18500-x","article-title":"GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of G(s) and G(q\/11)","volume":"11","author":"Abboud","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.beem.2024.101892_bib243","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/me.2013-1203","article-title":"GnRH-(1-5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor","volume":"28","author":"Cho-Clark","year":"2014","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib244","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI131609","article-title":"GPR101 mediates the pro-resolving actions of RvD5n-3 DPA in arthritis and infections","volume":"130","author":"Flak","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beem.2024.101892_bib245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2023.108676","article-title":"GPR101: Modeling a constitutively active receptor linked to X-linked acrogigantism","volume":"127","author":"Costanzi","year":"2024","journal-title":"J Mol Graph Model"},{"key":"10.1016\/j.beem.2024.101892_bib246","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/ERC-15-0478","article-title":"GHRH excess and blockade in X-LAG syndrome","volume":"23","author":"Daly","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib247","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12020-015-0804-6","article-title":"Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome","volume":"51","author":"Naves","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101892_bib248","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1210\/jc.2015-3129","article-title":"Whole-Genome Sequencing of Growth Hormone (GH)-Secreting Pituitary Adenomas","volume":"100","author":"Valimaki","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib249","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2017-02287","article-title":"Genomic alterations and complex subclonal architecture in sporadic GH-secreting pituitary adenomas","volume":"103","author":"Hage","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib250","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1158\/1078-0432.CCR-17-2206","article-title":"The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes","volume":"24","author":"Salomon","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beem.2024.101892_bib251","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s42003-022-04272-1","article-title":"Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas\/somatotroph pituitary neuroendocrine tumors","volume":"5","author":"Yamato","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.beem.2024.101892_bib252","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41422-022-00736-5","article-title":"Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors","volume":"32","author":"Zhang","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.beem.2024.101892_bib253","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1210\/jcem-71-6-1416","article-title":"Clinical characteristics of acromegalic patients whose pituitary tumors contain mutant Gs protein","volume":"71","author":"Landis","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib254","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1126\/science.2116665","article-title":"Two G protein oncogenes in human endocrine tumors","volume":"249","author":"Lyons","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.beem.2024.101892_bib255","first-page":"677","article-title":"gsp mutations in human thyroid tumours","volume":"6","author":"Suarez","year":"1991","journal-title":"Oncogene"},{"key":"10.1016\/j.beem.2024.101892_bib256","first-page":"90","article-title":"G-protein oncogenes in acromegaly","volume":"38","author":"Spada","year":"1992","journal-title":"Horm Res"},{"key":"10.1016\/j.beem.2024.101892_bib257","first-page":"301","article-title":"Analysis of the Gs alpha gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues","volume":"129","author":"Hosoi","year":"1993","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.beem.2024.101892_bib258","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/365649a0","article-title":"Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas","volume":"365","author":"Parma","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.beem.2024.101892_bib259","first-page":"765","article-title":"Activating mutations of the Gs alpha-gene in nonfunctioning pituitary tumors","volume":"77","author":"Tordjman","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib260","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/1097-0142(19930815)72:4<1386::AID-CNCR2820720439>3.0.CO;2-J","article-title":"Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis","volume":"72","author":"Yoshimoto","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib261","doi-asserted-by":"crossref","first-page":"10488","DOI":"10.1073\/pnas.91.22.10488","article-title":"Oncogenic potential of guanine nucleotide stimulatory factor alpha subunit in thyroid glands of transgenic mice","volume":"91","author":"Michiels","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beem.2024.101892_bib262","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2362.1995.tb01537.x","article-title":"G-protein mutations in human pituitary adrenocorticotrophic hormone-secreting adenomas","volume":"25","author":"Williamson","year":"1995","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.beem.2024.101892_bib263","first-page":"1702","article-title":"G protein gene mutations in patients with multiple endocrinopathies","volume":"80","author":"Williamson","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib264","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2265.1995.tb01878.x","article-title":"Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue","volume":"42","author":"Yang","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib265","first-page":"2074","article-title":"Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors","volume":"83","author":"Fragoso","year":"1998","journal-title":"J Clin Endocr Metab"},{"key":"10.1016\/j.beem.2024.101892_bib266","first-page":"891","article-title":"Detection of gsp oncogene in growth hormone-secreting pituitary adenomas and the study of clinical characteristics of acromegalic patients with gsp-positive pituitary tumors","volume":"111","author":"Shi","year":"1998","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.beem.2024.101892_bib267","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1009905131334","article-title":"Clinical correlates in acromegalic patients with pituitary tumors expressing GSP oncogenes","volume":"1","author":"Buchfelder","year":"1999","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101892_bib268","first-page":"2872","article-title":"Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas","volume":"85","author":"Persani","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib269","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/mgme.2001.3290","article-title":"Somatic mutations in thyroid nodular disease","volume":"75","author":"Krohn","year":"2002","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.beem.2024.101892_bib270","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ghir.2004.10.001","article-title":"GSPalpha mutations in Mexican patients with acromegaly: potential impact on long term prognosis","volume":"15","author":"Mendoza","year":"2005","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.beem.2024.101892_bib271","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11102-007-0058-2","article-title":"Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission","volume":"10","author":"Freda","year":"2007","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101892_bib272","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11102-008-0136-0","article-title":"Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience","volume":"12","author":"Taboada","year":"2009","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101892_bib273","article-title":"Follicular thyroid carcinoma with NRAS Q61K and GNAS R201H mutations that had a good (131)I treatment response","volume":"2016","author":"Lu","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.beem.2024.101892_bib274","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1530\/EJE-16-0620","article-title":"Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas","volume":"176","author":"Ritvonen","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib275","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib276","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/gcc.22854","article-title":"Activating genomic alterations in the Gs alpha gene (GNAS) in 274 694 tumors","volume":"59","author":"Tirosh","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib277","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3803\/EnM.2020.875","article-title":"Associations of GNAS mutations with surgical outcomes in patients with growth hormone-secreting pituitary adenoma","volume":"36","author":"Jung","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.beem.2024.101892_bib278","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147570","article-title":"Somatotroph tumors and the epigenetic status of the GNAS locus","volume":"22","author":"Romanet","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beem.2024.101892_bib279","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrc3521","article-title":"The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer","volume":"13","author":"O'Hayre","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib280","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s11914-015-0268-x","article-title":"GNAS Spectrum of Disorders","volume":"13","author":"Turan","year":"2015","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.beem.2024.101892_bib281","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/modpathol.2017.88","article-title":"GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas","volume":"30","author":"Ritterhouse","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.beem.2024.101892_bib282","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.4251\/wjgo.v12.i9.1056","article-title":"Methylation changes at the GNAS imprinted locus in pancreatic cystic neoplasms are important for the diagnosis of malignant cysts","volume":"12","author":"Faias","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.beem.2024.101892_bib283","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1172\/JCI11887","article-title":"Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly","volume":"107","author":"Hayward","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.beem.2024.101892_bib284","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/jc.2004-0194","article-title":"Parental origin of Gsalpha mutations in the McCune-Albright syndrome and in isolated endocrine tumors","volume":"89","author":"Mantovani","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib285","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/ijc.22816","article-title":"Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment","volume":"121","author":"Picard","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib286","first-page":"2077","article-title":"Biochemical characteristics of human pituitary somatotropinomas with and without gsp mutations: in vitro cell culture studies","volume":"80","author":"Adams","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib287","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1210\/jcem-71-6-1421","article-title":"Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary-tumors with or without constitutively active adenylyl cyclase","volume":"71","author":"Spada","year":"1990","journal-title":"J Clin Endocr Metab"},{"key":"10.1016\/j.beem.2024.101892_bib288","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib289","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40478-020-01067-5","article-title":"Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis","volume":"8","author":"Lasolle","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.beem.2024.101892_bib290","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233846","article-title":"Transcriptomic classification of pituitary neuroendocrine tumors causing acromegaly","volume":"11","author":"Rymuza","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.beem.2024.101892_bib291","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s11102-015-0662-5","article-title":"Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis","volume":"18","author":"Efstathiadou","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101892_bib292","doi-asserted-by":"crossref","DOI":"10.1158\/1541-7786.MCR-19-0434","article-title":"Genetic and Epigenetic Characterization of Growth Hormone-Secreting Pituitary Tumors","author":"Valimaki","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.beem.2024.101892_bib293","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib294","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101892_bib296","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101892_bib297","first-page":"71","article-title":"Genetic testing in pituitary adenomas: what, how, and in whom?","volume":"66","author":"Daly","year":"2019","journal-title":"Endocrinol, Diabetes Y Nutr (Engl Ed)"},{"key":"10.1016\/j.beem.2024.101892_bib298","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/cen.14706","article-title":"Molecular genetic testing in the management of pituitary disease","volume":"97","author":"Coopmans","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib299","first-page":"10","article-title":"Genetics of acromegaly and gigantism","author":"Boguslawska","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.beem.2024.101892_bib300","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.ajhg.2023.06.009","article-title":"Beyond the exome: What's next in diagnostic testing for Mendelian conditions","volume":"110","author":"Wojcik","year":"2023","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2024.101892_bib301","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100947","article-title":"The landscape of reported VUS in multi-gene panel and genomic testing: Time for a change","volume":"25","author":"Rehm","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.beem.2024.101892_bib302","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajhg.2023.11.005","article-title":"Will variants of uncertain significance still exist in 2030","volume":"111","author":"Fowler","year":"2024","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.beem.2024.101892_bib303","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beem.2024.101892_bib304","doi-asserted-by":"crossref","DOI":"10.3390\/genes15010120","article-title":"Choosing the best tissue and technique to detect mosaicism in fibrous dysplasia\/McCune-Albright syndrome (FD\/MAS)","volume":"15","author":"Vado","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.beem.2024.101892_bib305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060525","article-title":"Quantitative and sensitive detection of GNAS mutations causing mccune-albright syndrome with next generation sequencing","volume":"8","author":"Narumi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2024.101892_bib306","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/jbmr.4766","article-title":"Identification of GNAS variants in circulating cell-free DNA from patients with fibrous dysplasia\/McCune Albright syndrome","volume":"38","author":"Roszko","year":"2023","journal-title":"J Bone Min Res"},{"key":"10.1016\/j.beem.2024.101892_bib307","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM198501033120103","article-title":"Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor","volume":"312","author":"Melmed","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101892_bib308","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1210\/jc.2011-2930","article-title":"Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a French nationwide series of 21 cases","volume":"97","author":"Garby","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib309","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2006-0561","article-title":"McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and\/or pegvisomant in somatostatin analog-resistant patients","volume":"91","author":"Galland","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib310","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1530\/EJE-07-0533","article-title":"Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene","volume":"157","author":"Naves","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib311","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000327831","article-title":"Clinical features and treatment of pediatric somatotropinoma: case study of an aggressive tumor due to a new AIP mutation and extensive literature review","volume":"75","author":"Personnier","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.beem.2024.101892_bib312","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11102-016-0732-3","article-title":"Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening","volume":"19","author":"Mangupli","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101892_bib313","doi-asserted-by":"crossref","DOI":"10.1530\/EC-19-0004","article-title":"AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients","author":"Daly","year":"2019","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2024.101892_bib314","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jc.2013-2868","article-title":"Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation","volume":"99","author":"Williams","year":"2014","journal-title":"J Clin Endocr Metab"},{"key":"10.1016\/j.beem.2024.101892_bib315","doi-asserted-by":"crossref","first-page":"luad028","DOI":"10.1210\/jcemcr\/luad028","article-title":"Effective long-term pediatric pegvisomant monotherapy to final height in X-linked acrogigantism","volume":"1","author":"Burren","year":"2023","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.beem.2024.101892_bib316","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2015-4366","article-title":"Somatic GPR101 duplication causing X-linked acrogigantism (XLAG)-diagnosis and management","volume":"101","author":"Rodd","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101892_bib317","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1677\/ERC-08-0142","article-title":"Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review","volume":"16","author":"Dworakowska","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101892_bib318","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3389\/fendo.2019.00837","article-title":"Clinical relevance of genetic analysis in patients with pituitary adenomas: a systematic review","volume":"10","author":"van den Broek","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.beem.2024.101892_bib319","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.beem.2024.101892_bib320","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2265.2012.04445.x","article-title":"Familial pituitary adenomas - who should be tested for AIP mutations?","volume":"77","author":"Korbonits","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101892_bib321","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8581626","article-title":"Emergence of pituitary adenoma in a child during surveillance: clinical challenges and the family members' view in an AIP mutation-positive family","volume":"2018","author":"Marques","year":"2018","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib322","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement","author":"Taieb","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2024.101892_bib323","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Taieb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:04:15Z","timestamp":1778616255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":323,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1521690X24000460"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101892","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic diagnosis in acromegaly and gigantism: From research to clinical practice","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101892"}}